Agile Therapeutics is a women's healthcare company. Co.'s primary product candidate, Twirla, also known as AG200-15, is a once-weekly prescription combination hormonal contraceptive patch that is at the end of clinical development. Twirla is a combined hormonal contraceptives patch that contains the active ingredients ethinyl estradiol, which is a synthetic estrogen, and levonorgestrel, which is a type of progestin, a synthetic steroid hormone. Co.'s pipeline consists of two classes of product candidates: Twirla line extensions and other transdermal contraceptive product candidates, including AG200-ER, AG200-SP, AG200-ER, and AG890. The AGRX stock yearly return is shown above.
The yearly return on the AGRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AGRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|